Dysfunctional immune circuits underlie many diseases, including cancer and autoimmunity. Current immunotherapies often target a single pathway or cell type, limiting their efficacy. Treatment of anti-PD-1 refractory solid tumors, including breast, colorectal, lung, and melanoma ca... Read more

A novel approach for enhancing the efficacy of PD-L1 targeting antibodies by harnessing beneficial FcγR signaling pathways. Strategy involves either (1) Co-administration of PD-L1 targeting antibodies with an FcγRIIB-blocking antibody or Enhanced anti-PD-L1 therapy for cancer tr... Read more

We disclose a novel approach to bypass dose-limiting toxicity of 4-1BB agonists, the major limiting factor for the clinical development of 4-1BB mAbs for cancer immunotherapy: mutating 4-1BB ligand to attenuate its potency and fusing it to an antibody targeting defined immune cells which con... Read more